| [1] |
Tang A, Hallouch O, Chernyak V , et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis[J]. Abdom Radiol (NY), 2018,43(1):13-25.
|
| [2] |
Raoul JL, Sangro B, Forner A , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization[J]. Cancer Treat Rev, 2011,37(3):212-220.
|
| [3] |
Nishikawa H, Kimura T, Kita R , et al. Radiofrequency ablation for hepatocellular carcinoma[J]. Int J Hyperthermia 2013,29(6):558-568.
|
| [4] |
Bruix J, Gores GJ, Mazzaferro V . Hepatocellular carcinoma: clinical frontiers and perspectives[J]. Gut, 2014,63(5):844-855.
|
| [5] |
Liu Y, Liu R, Wang P , et al. Percutaneous implantation of (125)iodine seeds for treatment of portal vein tumor thrombosis in hepatocellular carcinoma[J]. Med Oncol, 2015,32(8):214.
|
| [6] |
Xiao ZL, Wang P, Lei LP , et al.[ Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC][J]. Zhonghua Gan Zang Bing Za Zhi, 2019,27(9):732-736.
|
| [7] |
Han K, Kim JH . Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system[J]. World J Gastroenterol, 2015,21(36):10327-10335.
|
| [8] |
原发性肝癌诊疗规范(2017年版)[J]. 消化肿瘤杂志(电子版), 2017,9(04):213-228.
|
| [9] |
孙亭山, 李颖 . TACE联合二期手术切除巨块肝癌的临床疗效观察[J]. 中国医药指南, 2019,17(05):71-72.
|
| [10] |
盛波, 杨振华, 黄力建, 刘方颖, 龙建安, 李叶枚, 商健彪 . TACE术后联合二期手术治疗BCLC-B期肝癌的临床观察[J]. 中国医药指南, 2015, 13(16):49+58.
|
| [11] |
林福煌, 吴宁, 李斯锐 , 等. 介入治疗原发性肝癌合并不同类型动静脉瘘的影响因素[J]. 中国医学装备, 2018,15(11):82-86.
|
| [12] |
Chan SL, Chong CC, Chan AW , et al. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016[J]. World J Gastroenterol, 2016,22(32):7289-7300.
|
| [13] |
Kudo M, Matsui O, Izumi N , et al. Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update[J]. Oncology-Basel, 2014,87:22-31.
|
| [14] |
Raoul JL, Gilabert M, Piana G . How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective[J]. Liver Cancer, 2014,3(2):119-124.
|
| [15] |
Feng K, Ma KS . Value of radiofrequency ablation in the treatment of hepatocellular carcinoma[J]. World J Gastroenterol, 2014,20(20):5987-5998.
|
| [16] |
Fu C, Liu N, Deng Q , et al. Radiofrequency ablation vs. surgical resection on the treatment of patients with small hepatocellular carcinoma: a system review and meta-analysis of five randomized controlled trials[J]. Hepatogastroenterology, 2014,61(134):1722-1729.
|
| [17] |
Langenbach MC . RFA vs resection of HCC: exploring the past to improve the future[J]. Eur Radiol, 2019,29(5):2677-2678.
|
| [18] |
Nkontchou G, Seror O, Mahamoudi A , et al. Predictive factors of HCC free survival in 203 patients with cirrhosis classed Child Pugh A and HCC (<= 5cm) treated by radiofrequency ablation (RFA)[J]. J Hepatol, 2008,48:S154-S154.
|
| [19] |
王译斌, 廖锦堂, 李悦怡 , 等. 对比经皮微波消融与射频消融治疗肝癌疗效的Meta分析[J]. 中国医学影像技术, 2014,30(12):1869-1873.
|
| [20] |
Pan GZ, Xu JB, Hao L , et al.[ Effect of CIK on long-term survival in the treatment of HCC after RFA combined TACE][J]. Zhonghua Yi Xue Za Zhi, 2016,96(9):689-692.
|
| [21] |
Sun Y, Ji S, Ji H , et al. Clinical efficacy analysis of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in primary liver cancer and recurrent liver cancer[J]. J BUON, 2019,24(4):1402-1407.
|
| [22] |
杨柏帅, 袁敏, 陈天佑 , 等. 肝动脉化疗栓塞联合同步射频消融治疗中晚期肝细胞癌效果及预后影响因素分析[J]. 中华实用诊断与治疗杂志, 2019,33(07):678-681.
|
| [23] |
Guo W, He X, Li Z ,, et al. Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. Surgical Resection (SR) on Survival Outcome of Early Hepatocellular Carcinoma: A Meta-Analysis[J]. Hepatogastroenterology, 2015,62(139):710-714.
|
| [24] |
赵松, 陈学春, 龙清云 , 等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J]. 介入放射学杂志, 2013,22(11):908-913.
|
| [25] |
秦叔逵, 白玉贤, 欧阳学农 , 等. 阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验[J]. 临床肿瘤学杂志, 2017,22(12):1057-1065.
|
| [26] |
Chng SSY, Tan SWL, Lee JJX , et al. Response to multi-targeted kinase inhibitor (MKI) after immune checkpoint inhibitor (ICI) in patients with hepatocellular carcinoma (HCC)[J]. Ann Oncol, 2018,29.
|
| [27] |
Naidoo J, Page DB, Li BT , et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2016,27(7):1362.
|
